HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
about
Perspectives for therapeutic HPV vaccine developmentTLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.Trial Watch: Peptide-based anticancer vaccines.The present status and future prospects of peptide-based cancer vaccines.Immune therapy for human papillomaviruses-related cancers.Rhipicephalus microplus and Ixodes ovatus cystatins in tick blood digestion and evasion of host immune response.Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.Autologous vaccination for the treatment of equine sarcoids: 18 cases (2009-2014).Therapeutic Vaccine Strategies against Human Papillomavirus.Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates.Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies.Targeting neoantigens for cancer immunotherapyPotential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studiesHPV disease transmission protection and control.Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer.Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies.Current state in the development of candidate therapeutic HPV vaccinesVaccines for established cancer: overcoming the challenges posed by immune evasion.A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile.The importance of correctly timing cancer immunotherapy.The current state of therapeutic and T cell-based vaccines against human papillomaviruses.Peptide vaccines in cancer-old concept revisited.Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination.Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.Progress in vaccine development.The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.Protective cellular immunity generated by cross-presenting recombinant overlapping peptide proteins.Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015.Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.Therapeutic vaccines for high-risk HPV-associated diseases.Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice.HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia.
P2860
Q28069272-6BAD6208-9864-4422-90E6-2D5E8903900CQ30841163-04CC9CDF-7BD3-4F22-B18B-92D24A6533C8Q34483345-45D02D8E-9854-44ED-ABCF-4D4338163E46Q34528638-8C4A11EF-528B-44CD-B1DB-B27F98390AABQ34657561-6472F94E-187B-400C-BE6B-E07E3DD24DD5Q35122741-55E933FD-ABBD-4EFE-896E-B0E5F0DFC373Q35563824-8FE559AC-9763-4554-BC0E-AF276D479502Q35740600-78F58227-E65D-4324-99D2-5074FBE08C4EQ35826752-B9E3F499-3F93-464B-B9F1-A0CBBF485D92Q35838039-B6F559B0-944C-4E66-B1F5-9CFB01F5FC68Q35864569-A129CE10-6B7D-4454-BD83-4785F4A74069Q36154471-A9D8DE91-B5EA-4A57-A1D0-4A2B91513778Q36998205-EB1955C0-3A4B-4C25-98AE-04E1B2A467BAQ37010987-C5118DA9-7143-4080-86C7-907BF3F5EDB0Q37223669-CFFB1FAE-D979-4B37-A8E0-30607B3AEAE2Q37399278-D8282F9F-CE18-4D08-B09A-1D2E268EFCAAQ37494787-23F21DD9-EA32-43C7-A506-63209792772DQ37705703-923CD942-8A2B-42AD-B0FC-70E13BC2ECC8Q38168904-9C83CC58-64D4-44A5-8A1A-CE3FF5650224Q38196935-2C2BCAC8-554E-4D8F-8BF5-A86631096E16Q38743922-C8978A46-882E-41C0-B9D8-7A1A0D1D890BQ38769021-48D87543-B4A2-4AA8-B9C1-32B5BF60072FQ38926456-73C732DB-17F3-4B2C-90AC-5B17F53EF26CQ38995979-D5636ED0-FF01-4912-B355-7F948F16FA11Q39033576-58691BBE-35F2-4AEC-A415-5828C9262B1CQ39035351-E799962F-1E7C-4574-8279-810DD30C6670Q40242985-769696E0-3315-42E6-9882-2498530E2731Q40765193-31183EB9-E7E0-4C4A-992A-169F65792E7DQ40788906-E3F8D46D-4734-4C4C-8647-CCEFF79EFCEAQ40802250-79D4A506-98F8-401A-BE81-C2E5B459DAF5Q41067857-4C002092-82BC-4808-9D16-41534F2EC7C7Q41510529-08987EA4-C293-4F7F-AAE3-5504A4884823Q42255546-B8121BE8-E94A-40DF-A397-5A3ED4655296Q42336210-E8A8C29F-03D2-4916-899B-413B426E91ACQ42938763-B9FDB07E-CC79-47B2-9E7A-690B6C9C314FQ47130393-09635B9B-37AC-47A0-B3CB-FBA57D6E3F00Q47139657-62E559CD-A248-4434-88E7-FE13C0C6A17EQ47255618-78E758DE-FCC5-4F45-848E-C713BF6BCB91Q47559036-B789A677-EB5C-4F79-9E50-20FBBEFCA933Q47797636-401BF781-B94E-4E7B-AE1F-010D2F9EDBAE
P2860
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
HPV16 synthetic long peptide ( ...... l carcinoma, a phase II trial.
@ast
HPV16 synthetic long peptide ( ...... l carcinoma, a phase II trial.
@en
type
label
HPV16 synthetic long peptide ( ...... l carcinoma, a phase II trial.
@ast
HPV16 synthetic long peptide ( ...... l carcinoma, a phase II trial.
@en
prefLabel
HPV16 synthetic long peptide ( ...... l carcinoma, a phase II trial.
@ast
HPV16 synthetic long peptide ( ...... l carcinoma, a phase II trial.
@en
P2093
P2860
P356
P1476
HPV16 synthetic long peptide ( ...... l carcinoma, a phase II trial.
@en
P2093
A Rob P M Valentijn
Cornelis J M Melief
Dorien M A Berends-van der Meer
Edith M G van Esch
Els L van Persijn van Meerten
Gert Jan Fleuren
Gijs Kerpershoek
Jaap Oostendorp
Linda F M Stynenbosch
Lorraine M Fathers
P2860
P2888
P356
10.1186/1479-5876-11-88
P50
P577
2013-04-04T00:00:00Z
P5875
P6179
1045094221